Inflabloc Raises $6M

Salt Lake City, Utah-based Inflabloc Pharmaceuticals has raised $6M in a Series C funding. The company said this morning that the round was led by Friedli Corporate Finance and vSpring Capital. Inflabloc is developing biopharmaceuticals targeting inflammatory diseases. The company said that the funding will be used to fund Phase II clinical studies of its lead compount, used for the treatment of Crohn's disease and hyperlipidemia. The funding comes at the completion of the company's merger with MantiCore Pharmaceuticals. More information »